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Background and Purpose: An important minority of cerebral small vessel disease (cSVD) is 
monogenic. Many monogenic cSVD genes are recognized to be associated with extra-
cerebral phenotypes. We assessed the frequency of these phenotypes in existing literature.   
Methods: We performed a systematic review following the PRISMA guidelines, searching 
Medline/Embase for publications describing individuals with pathogenic variants in 
COL4A1/2, TREX1, HTRA1, ADA2 and CTSA genes (PROSPERO 74804). We included any 
publication reporting on ≥1 individual with a pathogenic variant and their clinically-relevant 
phenotype. We extracted individuals’ characteristics, and information about associated extra-
cerebral phenotypes and stroke/TIA. We noted any novel extra-cerebral phenotypes and 
looked for shared phenotypes between monogenic cSVDs.  
Results: After screening 6048 publications, we included 96 COL4A1 (350 individuals), 32 
TREX1 (115 individuals), 43 HTRA1 (38 homozygous/61 heterozygous individuals), 16 
COL4A2 (37 individuals), 119 ADA2
 
(209 individuals) and 3 CTSA
 
(14 individuals) 
publications. The majority of individuals originated from Europe/North America, except for 
HTRA1, where most were from Asia. Age varied widely, ADA2 individuals being youngest 
and heterozygous HTRA1/CTSA individuals oldest. Sex distribution appeared equal. Extra-
cerebral phenotypes were common: 14% to 100% of individuals with a pathogenic variant 
manifested at least one extra-cerebral phenotype (14% COL4A2, 43% HTRA1 heterozygotes, 
47% COL4A1, 57% TREX1, 91% ADA2, 94% HTRA1
 
homozygotes and 100% CTSA 
individuals). Indeed, for 4 of 7 genes an extra-cerebral phenotype was observed more 
frequently than stroke/TIA. Ocular, renal, hepatic, muscle and hematological systems were 
each involved in more than one monogenic cSVD. 
Conclusions: Extra-cerebral phenotypes are common in monogenic cSVD with extra-






















    
    
    
    
    
    
    
    







literature mean that further data from large-scale population-based longitudinal studies 
collecting health outcomes in a systematic unbiased way is warranted.  The emerging 
knowledge will help to select patients for testing, inform clinical management, and provide 
further insights into the underlying mechanisms of cSVD.  
 
Non-standard Abbreviations and Acronyms: 
cSVD = cerebral small vessel disease  
CADASIL = cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy  



































    
    
    
    
    
    
    
    








Non-amyloid cerebral small vessel disease (hereafter referred to in this report as cSVD) is a 
term used to describe a variety of pathological processes that affect the deep small 
penetrating arteries, arterioles, venules and capillaries of the brain. The main clinical 
phenotypes of cSVD include small vessel ischemic stroke, deep intracerebral hemorrhage and 
vascular cognitive impairment. It can also manifest as a primarily radiological syndrome, 
with lesions in the subcortical regions of the brain
1,2
. The overall burden of cSVD is growing 
as the world’s population continues to age. Other than management of hypertension, we 
currently lack effective treatments to reduce the risk of cSVD
2
. Hence pathways involved in 
cSVD pathogenesis must be better understood to develop new effective prevention and 
treatment strategies.  
A minority of cSVD is monogenic – i.e. caused by rare pathogenic variants in several genes 
thought to cause cSVD as a primary syndrome or a dominant feature alongside other systemic 
manifestations
3
. The first such gene discovered was NOTCH3 in 1996, causing cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL)
4
. Subsequently, over the last >20 years, further genes have been reported, 
including (in order of their discovery) COL4A1, TREX1, HTRA1, COL4A2, ADA2 and CTSA. 
Although these genes are known for causing a primarily cSVD phenotype, all but NOTCH3 
are also recognized to a smaller or larger extent to be associated with symptomatically 
manifest extra-cerebral phenotypes, and there is evidence of NOTCH3 associated 
asymptomatic skin involvement in CADASIL
5,6
. Understanding which genes are associated 
with which extra-cerebral phenotypes, and knowing the proportion of individuals with a 
pathogenic variant in these genes who exhibit specific phenotypes during their lifetime (i.e. 
genetic variant penetrance), can inform the selection of patients to test for monogenic 






















    
    
    
    
    
    
    
    







affected and non-affected family members. In addition, improved understanding of 
monogenic cSVDs has broader implications for the direction of future research into common 
cSVD. Finally, as treatment options for ADA2-related disease already exist
7
, and are 
emerging for other monogenic cSVDs (e.g. phenyl butyric acid for COL4A1
8
, and an 
anthracycline antibiotic for TREX1-associated disease 
[https://clinicaltrials.gov/ct2/show/study/NCT02723448]), understanding the full phenotypic 
spectrum of monogenic cSVD manifestations is of utmost importance in enabling relevant 
studies to monitor treatment effects and side effects. For example, preventative oral treatment 
of Col4a1 mutant mice with phenylbutyric acid has shown differential effects on different 
organ system pathologies, reducing adult ICH with no effect on eye and kidney defects
8
.   
We undertook a systematic review of the literature, aiming to identify all reported individuals 
with a pathogenic variant in a monogenic cSVD gene, and to summarize their extra-cerebral 
disease phenotypes. Our aim was to: (i) improve our understanding of the frequency of 
already recognized associated extra-cerebral phenotypes; (ii) discover novel extra-cerebral 
phenotypes; and (iii) search for shared clinical presentations between different monogenic 
cSVDs. 
Methods 
All supporting data are available within the article and its online supplementary files. 
Study protocol 
The present study is a systematic review including all known monogenic cSVD genes, whose 
protocol is available on PROSPERO 
(https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=74804). In this 






















    
    
    
    
    
    
    
    







dominant phenotype and are associated with at least one clinically-relevant extra-cerebral 
phenotype. We followed the PRISMA guidelines.  
Search strategy  
We searched Ovid Medline and Embase (from inception until July 2019) for publications 
about humans with pathogenic variants in COL4A1, TREX1, HTRA1, COL4A2, ADA2 and 
CTSA genes. Our search strategy included: (a) text words, phrases and Medical Subject 
Headings (MeSH) for relevant monogenic syndromes/diseases associated with variants in 
these genes; or (b) text words, phrases and MeSH terms associated with cSVD combined 
with those for genes of interest and their proteins 
(https://www.ahajournals.org/journal/str:Appendix I). We also checked the bibliographies of 
all relevant studies and reviews identified and used Google Scholar for forward citation 
searching. We included conference abstracts and foreign language publications. At least two 
authors (DEH, IK, BW, KR) screened all publications, reviewing all titles and abstracts and 
full texts as required. They worked ind pendently, blinded to each other’s decisions, and then 
reviewed disagreements through discussion and mutual consensus.  
Study inclusion and exclusion criteria 
We included all publications of any type (including abstracts, letters, clinical notes, 
comments, case reports, original articles describing case series or other study designs) that 
reported on ≥1 human individual(s) (hereafter referred to as ‘individuals’) who were 
















described clinically-relevant phenotype(s) of the included individual(s). 
From each eligible publication we included individuals carrying a variant which the study 






















    
    
    
    
    
    
    
    







relevant phenotype(s). This reporting could range from a simple comment to say that an 
individual was ‘healthy’ (e.g. asymptomatic family members of affected individuals) to a 
detailed case report. We excluded individuals whose variant was not confirmed by 
genotyping and those with a presumed pathogenic variant in ≥1 gene. We excluded 
publications studying only non clinically-relevant or purely radiological phenotypes (e.g. 
studies performing specialized psychological tests or measurements of specific brain 
structures). Where the same individual(s) were described in >1 publication, we included each 
individual only once, summarizing the information from all relevant publications.  
Data extraction  
From each included publication, we extracted data on the first author, publication year, 
journal and number of eligible individuals and pedigrees.   
For each eligible individual, we extracted data on their genetic variant and the resulting 
amino acid change (if relevant), country of origin and ethnicity, sex, age at clinical 
assessment, clinically-relevant extra-c rebral phenotype(s) and stroke, and age at respective 
phenotype diagnosis. 
One of KR, DEH, ST, QGK or IK extracted data from each publication. To assess agreement 
in assigning the status of major phenotype groups, at least two members of the team extracted 
data from 10% of publications, working independently and blinded to each other’s decisions. 
Data synthesis  
We counted the number of relevant publications (overall and by specialty), pedigrees, 
individuals and variants per gene. We summarized the characteristics of the individuals for 
each gene, including their geographic region of origin, sex and age at assessment (mean, 






















    
    
    
    
    
    
    
    







We looked up variant frequencies among the gnomAD database v2.1.1 non-neuro 101,605 
participants
9
, summarizing the proportion of variants present with any allele frequency, and 
the proportion of variants with allele frequencies of >0.1% and >0.5% for autosomal 
dominant and recessive inheritance mode genes respectively. The 0.1% and 0.5% thresholds 
were chosen as a pragmatic cut-off suggestive of the possibility of the variant being benign 
and we performed subgroup analyses to see if excluding these variants changes the overall 
results. 
For each gene, we summarized the clinically-relevant phenotype (hereafter referred to in this 
report as ‘phenotype’) data with respect to frequency (i.e. the percentage of individuals with a 
pathogenic variant in whom the respective associated phenotype was reported). We did not 
make assessments at the variant level because of the high proportion of private variants (e.g. 
variants described in only one pedigree) with only small numbers of pedigrees and 
individuals.  
Frequency of already recognized associated extra-cerebral phenotypes and of 
stroke/transient ischemic attack (TIA) 
We used the Online Mendelian Inheritance in Man database (OMIM, 





and COL4A1/COL4A2 as applying to both genes 
respectively), that are already recognized to be associated with pathogenic variants in that 
gene (https://www.ahajournals.org/journal/str:Table I, Appendix II). Our primary definition 
of hemorrhagic stroke for these purposes included porencephaly. We performed additional 
subgroup analyses excluding individuals presenting only with porencephaly, because while it 
often occurs as a result of intracerebral hemorrhage, it may also result from other destructive 
influences.
10
 For these selected extra-cerebral phenotypes and for stroke/TIA (including 






















    
    
    
    
    
    
    
    







absence versus uninvestigated status of the phenotype. A phenotype was considered 
uninvestigated if no mention was made about its presence or absence. We assessed whether 
the proportion of uninvestigated individuals for each phenotype changed significantly when 
excluding individuals reported only in abstract form (Fisher’s exact test significance p-value 
≤0.01). 
Novel potentially associated extra-cerebral phenotypes 
We identified extra-cerebral phenotypes not already recognized by OMIM, and considered 
these potentially associated when reported in >5% of individuals and ≥2 pedigrees per gene. 
We selected the 5% cut-off as a pragmatic method to identify phenotypes of potential 
interest, due to the substantial challenges in obtaining robust estimates of background disease 
prevalence in populations of different ethnicities and age for comparison. (Indeed, even if 
such robust estimates were available, meaningful comparison with the reported frequency 
among individuals in this study would be limited by incomplete age/ethnicity reporting). 
Based on the clinical expert knowledg  of the authors, we also noted any particularly rare or 
unusual disease phenotypes present in ≥2 individuals from ≥2 pedigrees. 
Shared extra-cerebral phenotypes between monogenic cSVDs 
We looked for shared patterns and differences in extra-cerebral manifestations among the 
monogenic cSVD genes. We stratified these manifestations into presumed vascular versus 
other phenotypes, and by anatomical organ system involvement 
(https://www.ahajournals.org/journal/str:Supplemental methods). We also explored 
























    
    
    
    
    
    
    
    







From 6048 publications identified for screening, we included 305 eligible publications: 96 
COL4A1, 32 TREX1, 25 HTRA1
HomZ
, 16 COL4A2, 119 ADA2, 18 HTRA1
HetZ
, and three CTSA 
publications (Figure 1). As expected, there was a positive correlation between the number of 
years since the gene was first discovered and the number of publications to date 
(https://www.ahajournals.org/journal/str: Figure I). An exception was ADA2, which was first 
reported as recently as 2013 but still has the largest number of publications. A likely 
explanation is the combination of existing treatment options and the severe early-onset 
systemic phenotype of ADA2, prompting more widespread genetic testing. The percentage of 
publications in specialist neurology or stroke journals varied by gene from 7-100% (ADA2 




 94%; CTSA 
100%). The number of individuals per gene ranged from 14 (CTSA) to 350 (COL4A1) and the 
number of pedigrees from three (CTSA) to 191 (COL4A1).  The proportion of pedigrees 





 79%; COL4A2 83%) (Figure 2). 
We identified 0% to 25% variants per gene in the gnomAD database, however only one 
COL4A1 variant and three COL4A2 variants were present at allele frequencies >0.1% 
(https://www.ahajournals.org/journal/str:Table II).  
Summary of individuals’ characteristics  
The majority (or all) of COL4A1, TREX1, COL4A2, ADA2 and CTSA individuals were 
European or North American (77%[239/309], 66%[76/115], 65%[22/34], 61%[121/200] and 
100%[14/14] respectively), while the majority (76%[29/38]) of HTRA1
HZ
 and just over a half 
(54%[33/61]) of HTRA1
HetZ
 individuals were Asian. However, data on individuals’ 
geographic region of origin was not reported for over a quarter of individuals for 5/7 genes; 
in these cases it was assumed from the first author’s country of origin (Table 1). Where the 






















    
    
    
    
    
    
    
    







gene), sex distribution was generally approximately equal (44-50% female) (Table 1). Data 
about the age at the time of assessment was missing for over a quarter of COL4A1, TREX1 
and HTRA1
HomZ 
individuals. Accepting this limitation, mean (median) age ranged from 17 
(13) years for the 209 ADA2 individuals to 60 (61) years for the 61 HTRA1
HetZ 
individuals. 
Age ranges were very broad for COL4A1, COL4A2 and ADA2, ranging from less than one to 
over 70 years. (Table 1). Age at specific phenotype diagnoses was generally not reported, 
hence it was not possible to comment on typical ages of phenotype presentation 
(https://www.ahajournals.org/journal/str: Table VI).  
Frequency of already recognized associated extra-cerebral phenotypes  
Comparison of results of the dual extraction showed 95% agreement.  
On an individual-level, extra-cerebral phenotypes were common: 14-100% of individuals per 
gene were reported to manifest at least one associated extra-cerebral phenotype (COL4A2 
14%[5/37]; HTRA1
HetZ 
43%[26/61]; COL4A1 47%[147/311]; TREX1 57%[21/37]; ADA2 
91%[187/205]; HTRA1
HomZ
 94%[33/35] and CTSA 100%[14/14]) (Figure 3). Excluding six 
COL4A2 and one COL4A1 individuals carrying variants with allele frequencies of >0.1% in 
the gnomAD population changed these proportion to 16% for COL4A2 (3/31 individuals) 
while the proportion for COL4A1 remained the same (47%, 147/310 individuals).  
The frequency of specific extra-cerebral phenotypes ranged widely across genes: 3-19% for 
COL4A1; 0-68% for TREX1; 37-74% for HTRA1
HomZ
; 0-8% for COL4A2; 11-66% for ADA2; 
7-31% for HTRA1
HetZ
; and 64-93% CTSA (Figure 4, 
https://www.ahajournals.org/journal/str:Figure II). Detailed definitions of included 
phenotypes are available from https://www.ahajournals.org/journal/str: Table I. 
For 4/7 genes (TREX1, HTRA1
HomZ
, ADA2, CTSA) an extra-cerebral phenotype was reported 






















    
    
    
    
    
    
    
    







Frequency of stroke/TIA  
The frequency of stroke/TIA ranged from 40-57% for five genes (ADA2, COL4A1, 
HTRA1
HetZ
, CTSA and COL4A2). In contrast, only 26% (10/38) of HTRA1
HomZ
 and 4% 
(5/115) of TREX1 individuals were reported to have suffered a stroke/TIA. The latter 
proportion did not include episodes of progressive neurological deficit characteristic for 
TREX1, often also attributed to an underlying vascular cause. The majority of COL4A1/2 
strokes (73%[115/157] and 100%[21/21] respectively) were hemorrhagic, while ischemic 
stroke/TIA was more commonly reported for the other genes. Hemorrhagic stroke remained 
the most common stroke type for COL4A1/2 individuals when excluding those presenting 
only with porencephaly. (Figure 4, https://www.ahajournals.org/journal/str:Table III, Figure 
II). 
Proportion of individuals with uninvestigated phenotypes 
We estimated the proportion of individuals where a phenotype was uninvestigated, and 
therefore its presence or absence unknown. This proportion ranged from 49-96% for 
COL4A1, 20-98% for TREX1, 11-63% for HTRA1
HomZ
, 43-100% for COL4A2, 26-86% for 
ADA2, 16-89% for HTRA1
HetZ
, and 0-7% for CTSA phenotypes 
(https://www.ahajournals.org/journal/str: Figure II). There was no statistically significant 
difference when excluding individuals reported only in an abstract form, except for 
degenerative spine disease in HTRA1
HomZ
 individuals (37% vs 8% uninvestigated individuals 
in all publications versus in publications excluding abstracts, respectively) 
(https://www.ahajournals.org/journal/str:Table IV).  
Novel potentially associated extra-cerebral phenotypes  
For the complete list of novel potentially associated extra-cerebral phenotypes see 






















    
    
    
    
    
    
    
    







associations were: COL4A1 and congenital kidney/urinary tract anomalies; TREX1 and 
hypertension, anemia, gastrointestinal bleeding; ADA2 and arthritis/arthralgia, 
lymphadenopathy, Diamond Blackfan anemia; and CTSA and venous thrombosis. Concerning 
rare disease phenotypes, two COL4A1 individuals had spontaneous bleeding into extra-
cerebral organs, and two TREX1 individuals had avascular bone necrosis in the absence of 
risk factors, suggestive of a systemic vulnerable vasculature
11
.  
Shared extra-cerebral phenotypes between monogenic cSVDs 
Of the vascular phenotypes, Raynaud’s phenomenon and ocular, renal and hepatic 
involvement were reported in association with ≥2 monogenic cSVD genes. Among non-
vascular phenotypes, muscle and hematological pathologies were reported in association with 
≥2 monogenic cSVD genes. (Table 2). 
Protein expression data from the Human Protein Atlas and Human Proteome Map projects 
did not clearly correspond to these phenotype associations. However, interpretation is limited 
by incomplete coverage of genes of interest as well as of tissue and cell types in the included 
experiments (https://www.ahajournals.org/journal/str:Figure III).  
Discussion 
To our knowledge, this is the first systematic review to summarize extra-cerebral 
manifestations across a range of monogenic cSVD genes. We found that extra-cerebral 
manifestations were frequently reported, in many cases more often than stroke/TIA. We also 
found shared extra-cerebral phenotypes between monogenic cSVDs caused by variants in 
different genes. Our results suggest that genes traditionally viewed as monogenic stroke 
genes may be more appropriately viewed as genes underlying a systemic monogenic 






















    
    
    
    
    
    
    
    







Extracerebral phenotypes appeared common despite: (i) >40% of publications coming from 
neurology/stroke journals, which might favor the reporting of cerebral over extra-cerebral 
phenotypes; (ii) a large proportion of individuals with uninvestigated phenotypes, meaning 
the true prevalence of these phenotypes may be even higher than estimated.  
The observation of widespread pleiotropy of monogenic cSVD genes has implications for 
clinical practice when diagnosing and managing patients with stroke. It should also inform 
research into the pathogenesis of monogenic cSVD genes more broadly. Although these 
genes have distinct functions, several of them may ultimately converge on a common 
pathologic pathway affecting the cerebrovascular (and perhaps more general vascular) 
matrisome to produce the cSVD phenotype.
12
 Future research may also identify shared 
mechanisms for the array of extra-cerebral manifestations. Finally, observations from large-
scale genetic associations studies have shown common variation in monogenic cSVD genes 
to be associated with sporadic cSVD.
13-16
 Whether the same applies to their pleiotropic 
associations is yet to be seen, but examples are beginning to emerge in the common disease 




The high proportion of private variants, together with the observation that this proportion has 
not fallen over time, is also noteworthy, particularly as regards the design of gene panels for 
clinical testing. The continuing emergence of novel pathogenic variants suggests that 
sequencing-based gene panels may be preferable over known variant microarray genotyping.  
The predominance of individuals originating from Europe/North America could suggest a 
higher prevalence among European origin populations. Alternatively, it could arise from the 
widespread issue of research bias in genetics research, where these populations are the most 
widely studied. In contrast to other genes, HTRA1 variants appeared more common in Asia, 
and in this case, the first report of HTRA1
 






















    
    
    
    
    
    
    
    







subsequent further testing towards individuals of this ethnicity. This potential for testing bias 
is supported by the observation that pathogenic HTRA1
 
variants have a higher frequency in 





 individuals appeared to have a lower frequency of stroke/TIA than HTRA1
HetZ 
individuals (26%[10/38] versus 56%[34/61], respectively). This difference may be caused 
due to selective testing bias, since the first publication of HTRA1 pathogenic heterozygous 
variants did not report an association with extra-cerebral features
19
, as well as by the higher 
mean age of HTRA1
HetZ 
individuals.  
All genes apart from ADA2 are expressed more broadly than in the brain. ADA2 is primarily 
expressed by blood cells. Therefore, it is not surprising that these genes have prevalent 
manifestations extra-cerebrally. It is interesting however that NOTCH3, which has a vascular 
expression broader than the brain, leads to a primarily brain-restricted phenotype. It has been 
suggested that vessel-specific expression of the matrisome may explain some of the variable 
clinical presentations and research into these expression patterns might provide further 
insights.
12
   
The strengths of our study are: (1) a comprehensive search strategy including abstracts and 
foreign language papers; (2) a systematic approach to data extraction, including consideration 
the proportion on individuals for whom the phenotype is uninvestigated; (3) a consistent 
approach not limited to just one gene, but across several cSVD genes to allow similarities and 
differences to be assessed. As such, our review complements the knowledge from other 





Our study also has some limitations: (1) the focus of this work on extra-cerebral phenotypes 
meant that we included only stroke and TIA as the cerebral manifestations of cSVD 






















    
    
    
    
    
    
    
    







thresholds for normal versus pathological); (2) we looked at gene-phenotype level 
associations rather than variant-phenotype associations because of small numbers of reported 
individuals with non-private variants; (3) our stringent efforts to avoid double counting of 
any individual means that we may have underestimated the overall number of individuals; (4) 
poor case characterization (including geographic origin and ethnicity) in many included 
studies; (5) the inherent biases of case reports and series including case investigation, 
publication and reporting biases; (6) we considered any variant pathogenic if reported as such 
by the author, hence may have included variants with less supportive evidence of 
pathogenicity. However, subgroup analyses informed by allele frequencies in the gnomAD 
population did not change the overall conclusions.   
Our study highlights some general challenges of interpreting research into gene-disease 
associations for rare monogenic disease. First, case reports are often difficult to publish, 
limited by word count, and lack a reporting structure. Guidelines (e.g. CARE guidelines)
22,23
 
for publishing case reports are not always enforced and are generally aimed at case reports of 
treatment effects
24
 rather than reports of r re genetic diseases (e.g. the guidelines lack advice 
about reporting mutation details, case ethnicity, and age of phenotype onset). Second, such 
reports are inherently biased, because case selection for investigation is not random, and 
diagnosed cases are more likely to be reported in publications if they are part of a large case 
series or present a novel phenotype. Third, due to small numbers of rare disease cases, true 
disease associations are difficult to establish, and alleged associations may arise through 
chance. Existing specialist-curated databases such as OMIM have established various criteria 
trying to overcome this, but even these involve subjectivity and are difficult to reproduce
25
.  
A study design that could overcome some of these issues is a large-scale population-based 
longitudinal study, where genetic information and health outcomes are collected in a 






















    
    
    
    
    
    
    
    







bio-samples yielding genetic data at scale, such as the UK Biobank (www.ukbiobank.ac.uk), 
will allow further assessment of the true clinical consequences of rare variants in monogenic 
cSVD genes, complementing the knowledge acquired from more traditional case reports and 
series.  
In conclusion, we found that extracerebral phenotypes are common in monogenic cSVD. This 
knowledge can help select patients for testing for the genetic variants as well as inform 
clinical management of already diagnosed cases (e.g., encourage screening for pre-
symptomatic extra-cerebral involvement). Notwithstanding the difficulties in establishing 
gene-disease associations robustly, we found new relationships of potential interest between 
monogenic cSVD genes and extra-cerebral phenotypes. Finally, we highlight common 
phenotype patterns across different monogenic cSVDs, where further research may provide 
additional mechanistic insights. We recommend that future investigations should focus on 
emerging population-based longitudinal resources to complement the existing insights gained 
from more traditional study designs for rare disease.  
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Figure 1. Selection of included studies.  
HetZ=heterozygous; HomZ=homozygous/compound heterozygous; *Reference lists and 
Google Scholar search. †We identified CADASIL (NOTCH3), FOXC1 and PITX2 
individuals as part of another systematic review but excluded them for this review (see 
Methods, Study protocol). ‡Four publications reported both COL4A1/2 individuals, hence the 
total number of unique publications (305) is not the sum total of publications per gene (309). 
112/305 publications were conference abstracts: COL4A1/2 (28), TREX1 (10), HTRA1
HomZ
 
(4), CECR1 (65), HTRA1
HetZ
 (5);  
Figure 2. Number of included individuals and pedigrees. 
Year=year gene first reported to be associated with cSVD; HetZ=heterozygous; 
HomZ=homozygous/compound heterozygous; N=number of publications; n/r=not reported; 
This figure is reporting on the DNA change, not the resulting amino acid change. Where the 
DNA change was not reported, the individual was included but variant considered ‘n/r’. For 
compound heterozygotes, if either of the variants was private, the pedigree was considered to 
carry a private variant. Where a range is given for the number of variants/pedigrees, 
publications had not clearly reported these data (e.g. a publication reporting 5 cases with 
“pathogenic COL4A1 variants”, but not specifying the variants, could refer to 5 cases all 
carrying the same variant or each carrying a private variant, resulting in a range of 1-5 private 
variants). 
Figure 3. Proportion of individuals with an extra-cerebral phenotype 
HetZ=heterozygous; HomZ=homozygous/compound heterozygous; Nphenotype=number of 
individuals with ≥1 extra-cerebral phenotype; Nall=total number of individuals with relevant 






















    
    
    
    
    
    
    
    







Figure 4. Frequency of Stroke/TIA and Extra-Cerebral Phenotypes. 






























    
    
    
    
    
    
    
    







Table 1. Summary of case characteristics. 























































































































































(28/209) - - 
AGE AT TIME OF ASSESSMENT† 
Mean age 
(years) 
22 43 37 24 17 60 57 
Median age 
(years) 






















    
    
    
    
    
    
    
    













31% 13% 13% 24% 11% 5% 0% 
N=number of cases; HetZ: heterozygous; HomZ: homozygous/compound heterozygous;  
*
Region of origin was not reported and therefore assumed from the first author’s institution 
country for 199/350 COL4A1, 12/115 TREX1, 10/38 HTRA1
HomZ
, 17/37 COL4A2, 62/209 
ADA2 and 21/61 HTRA1
HetZ 
individuals. It was not reported or possible to derive this for 41 
COL4A1, 3 COL4A2 and 9 ADA2 individuals. If a case was reported to have a different 
region of origin/ancestry to that of the country where they lived, they were considered to be 
from their region of origin (e.g. a Chinese origin person living in USA was considered 
Asian). †If a mean age was available for a group of individuals, the overall summary estimate 
was weighted by the group size. ‡8 individuals had only a mean age reported, so they were 
included in the calculations for mean age, but not for median and age range.  Turkey as a 
region of origin was reported on specifically because of the high proportion of ADA2 



































Table 2. Shared extra-cerebral phenotypes across monogenic cSVDs 
 





COL4A1/COL4A2 were treated as applying to both genes respectively); ?=extra-cerebral phenotype is a novel potentially associated phenotype 
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not already recognized to be associated with the gene in OMIM database; HetZ=heterozygous; HomZ=homozygous/compound heterozygous; 
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